^
Association details:
| Biomarker: | FGFR2 mutation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug Class: | FGFR2 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
ctDNA-based genomic landscape analysis to evaluate molecular brake and gatekeeper mutations in FGFR2 alterations.
Published date:
05/25/2023
Excerpt:
We also identified CCA patients with FGFR2 fusions and one or more concurrent FGFR2 SNVs; primarily those in the kinase domain and associated with FGFRi resistance.
DOI:
10.1200/JCO.2023.41.16_suppl.3049
Source:
Title:
Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.
Excerpt:
19 total acquired mut in FGFR2 were detected at resistance in 5/8 pts (between 1-9 unique mut identified in each sample). All mut were located in the kinase domain....Acquired mut in FGFR2 are seen in pts who have developed resistance to targeted therapy.
DOI:
10.1200/JCO.2019.37.15_suppl.4096
